Table 1.
Patient demographics and outcome.
| Institution | TUM | UW | p-Value 1 | |
|---|---|---|---|---|
| Total Patients | 148 p | 158 p | ||
| Location | 1 | |||
| Extremity or trunk | 141/148 p (95.2%) | 154/158 p (97.4%) | ||
| Abdomen/retroperitoneal | 5/148 p (3.3%) | 2/158 p (1.3%) | ||
| Thorax | 1/148 p (0.6%) | 0/158 p (0%) | ||
| Head and neck | 1/148 p (0.6%) | 2/158 p (1.3%) | ||
| Age | 57.29 ± 17.48 | 53.91 ± 15.40 | 0.04 * | |
| Gender | ||||
| Female | 69/148 p (46.6%) | 95/158 p (60.2%) | 0.2 | |
| Male | 79/148 p (53.4%) | 63/158 p (39.8%) | ||
| T-Stage | ||||
| 1 | 25/148 p (16.8%) | 28/158 (17.7%) | 0.88 | |
| 2 | 123/148 p (83.2%) | 130/158 p (83.3%) | ||
| a | 13/148 p (8.7%) | 6/158 p (3.7%) | 0.09 | |
| b | 135/148 p (91.3%) | 152/158 p (96.3%) | ||
| M-Stage | ||||
| 0 | 140/148 p (94.6%) | 153/158 p (96.8%) | 0.40 | |
| 1 | 8/148 p (5.4%) | 5/158 p (3.2%) | ||
| N-Stage | ||||
| 0 | 145/148 p (98%) | 158/158 p (100%) | 0.11 | |
| 1 | 3/148 p (2%) | 0/158 p (0%) | ||
| Grading 2 | 0.16 | |||
| 1 | 52/148 p (35.1%) | 25/158 p (15.8%) | ||
| 2 | 36/148 p (24.4%) | 53/158 p (33.6%) | ||
| 3 | 60/148 p (40.5%) | 80/158 p (50.6%) | ||
| Tumor volume | 294.52 ± 442.07 | 320.0 ± 487.04 | 0.42 | |
| AJCC-Stage 3 | 0.47 | |||
| IA | 10/148 p (6.7%) | 5/158 p (3.1%) | ||
| IB | 42/148 p (28.3%) | 20/158 p (12.6%) | ||
| IIA | 11/148 p (7.4%) | 23/158 p (14.5%) | ||
| IIB | 5/148 p (3.3%) | 37/158 p (23.4%) | ||
| III | 72/148 p (48.6%) | 68/158 p (43.0%) | ||
| IV | 8/148 p (5.4%) | 5/158 p (3.16%) | ||
| Median OS | 37.37 mo | 45.8 mo | 0.25 | |
| Available imaging | ||||
| T1FsGd | 148 | 158 | ||
| T2FS | 130 | 158 | ||
Abbreviations: *: p-value < 0.05, AJCC: American Joint Committee on Cancer and the International Union for Cancer Control, m: median, p: patients, r: range, RT: radiation therapy. 1 Wilcoxon rank-sum test for continuous and ordinal variables, Fisher’s exact test for nominal variables, log-rank test for comparison of survival times. Corrected for multiple testing by Bonferroni correction (“p-value adjusted”). 2 According to the French Federation of Cancer Centers Sarcoma Group (FNCLCC). 3 Following AJCC staging system version 7 [50].